December 18, 2013 — Mobius Medical Systems LP announced the release of the latest version of its flagship software product Mobius3D. Features of version 1.3 include the new MobiusFX add-on, which provides clinicians with a better way to perform patient-specific QA. MobiusFX utilizes linear accelerator log files and Mobius3D’s independently developed collapsed-cone algorithm to determine the 3-D dose a patient will receive. The MobiusFX technique only requires enough time to deliver the beams, which can be as quick as one minute. This allows QA to be easily achieved during breaks between patients or over a lunch hour.
As the only true 3-D solution for patient specific QA, MobiusFX can also provide information that is not available from 2-D or quasi-3-D systems. Using DVH objectives from both Radiation Therapy Oncology Group (RTOG) protocols and Task Group 101, or an unlimited number of user-defined parameters, MobiusFX lets clinicians know whether their treatments are meeting protocols. Additionally, data from the machine delivery is compared to expected positions from the treatment planning system patient plan. This provides users confidence that all parameters were correctly transferred between the TPS and the linear accelerator. Moreover, MobiusFX is not just for pre-treatment checks, as QA can easily be performed with the patient in place, opening up the possibility of per-fraction verifications.
At the core of MobiusFX is Mobius3D, the first 3-D TPS and plan check system that works with all major linear accelerators (with support for Tomotherapy plan checks coming soon). Mobius3D offers features and benefits not available in basic MU software. Full 3-D dose calculations are performed using the patient computed tomography (CT). Dose-volume histogram (DVH) objectives, plan deliverability, gantry clearance and contouring errors are calculated and examined automatically. Mobius3D’s browser-based interface can be accessed with any modern browser, including tablets and smartphones, making it easy to evaluate results from both Mobius3D and MobiusFX.
For more information: www.mobiusmed.com
March 28, 2024 
